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Abstract: Siramesine (SRM) is a σ-2 receptor agonist which has been recently shown to inhibit growth of
cancer cells. Fluorescence spectroscopy experiments revealed two distinct binding sites for this drug in
phospholipid membranes. More specifically, acidic phospholipids retain siramesine on the bilayer surface
due to a high-affinity interaction, reaching saturation at an apparent 1:1 drug-acidic phospholipid
stoichiometry, where after the drug penetrates into the hydrocarbon core of the membrane. This behavior
was confirmed using Langmuir films. Of the anionic phospholipids, the highest affinity, comparable to the
affinities for the binding of small molecule ligands to proteins, was measured for phosphatidic acid (PA,
mole fraction of XPA ) 0.2 in phosphatidylcholine vesicles), yielding a molecular partition coefficient of 240
( 80 × 106. An MD simulation on the siramesine:PA interaction was in agreement with the above data.
Taking into account the key role of PA as a signaling molecule promoting cell growth our results suggest
a new paradigm for the development of anticancer drugs, viz. design of small molecules specifically
scavenging phospholipids involved in the signaling cascades controlling cell behavior.
Introduction
Siramesine (1′-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]-1-butyl]-
spiro[isobenzofuran-1(3H),4′-piperidine], SRM, Figure 1) was
originally synthesized by H. Lundbeck A/S for treatment of anxiety.
Phase II trials showed this compound to be nontoxic and well
tolerated in humans. However, the clinical efficacy was not
satisfactory, and its development was discontinued in 2002.1
The primary target of SRM has been suggested to be the σ-2
receptor,2 an orphan with no endogenous ligand known. These
receptors have unique drug interaction profiles binding, for
instance, haloperidol and sertraline, and their activity has been
associated with various psychiatric disorders.3 The physiological
functions of σ receptors remain unknown. The σ-1 receptor
has been cloned, whereas the σ-2 receptor still needs to be
isolated.4 The latter have been found to be associated with the
so-called lipid rafts.5 Interestingly, σ receptors are abundant in
many malignant cells, and there is evidence suggesting their
crucial role in cell proliferation.6 Along these lines, SRM has
been recently demonstrated to suppress growth of several cell
lines in vitro, and it has also been shown to inhibit growth of
solid tumors in mice.7
Several drugs used to treat psychiatric disorders and cancer
(e.g., haloperidol, chlorpromazine, clozapine, and doxoru-
bicin) bind avidly to phospholipids, acidic phospholipids in
particular.8,9 We studied the interactions of SRM with model
biomembranes composed of zwitterionic and anionic phos-
pholipids using fluorescence spectroscopy (employing the
intrinsic fluorescence of SRM as well as different fluorescent
lipid analogs), DSC, Langmuir balance, and molecular
dynamics (MD) simulations. Our results demonstrate a high-
affinity binding of SRM to phosphatidic acid. This interaction
is discussed in the context of the role of this phospholipid
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as a second messenger promoting cell growth, allowing
cancer cells to escape apoptosis.10,11
Materials and Methods
Chemicals. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC),1-palmitoyl-2-oleoyl-sn-glycero-3-(phospho-L-serine)(POPS),
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-rac-glycerol (POPG),
1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphoethanolamine (POPE),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoinositol (POPI), 1,2-di-
palmitoyl-sn-glycero-3-phospho[N-(4-nitrobenz-2-oxa-1,3-diaz-
olyl)]ethanolamine (DPPN), 1,2-dioleyl-sn-glycero-3-phosphoeth-
anol (DOPet), 1,2-dioleyl-sn-glycero-3-phosphomethanol (DOPmet),
1-stearoyl-2-hydroxy-sn-glycero-3-phosphate(Lyso-PA),and1-stearoyl-
2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] (Lyso-PG) were
from Avanti Polar Lipids (Alabaster, AL). 1-Palmitoyl-2-[10-(pyren-
1-yl)]decanoyl-sn-glycero-3-phosphocholine (PPDPC) was from
K&V Bioware (Espoo, Finland). SRM was kindly provided by H.
Lundbeck A/S (Copenhagen, Denmark). Deionized Milli-Q (Mil-
lipore, Bedford, MA) filtered water was used in all experiments.
Hepes, NaCl, EDTA, and egg yolk-phosphatidic acid (egg-PA) were
from Sigma. All chemicals were of analytical purity. The lipids
were analyzed by thin layer chromatography on silicic acid coated
plates, developed with chloroform/methanol/water/ammonia (65/
20/2/2, by volume) as the solvent. No impurities were detected upon
examination upon UV illumination or after iodine staining.
Lipid and drug concentrations were determined gravimetrically
using a high-precision microbalance (Cahn Instruments Inc.,
Cerritos, CA). The concentrations of PPDPC and DPPN were
determined from their absorption spectra (Cary-100 Bio, Varian
Inc., Victoria, Australia) recorded using quartz cuvettes with a 1
cm path length and employing 42 000 cm-1 at 342 nm and 21 000
cm-1 at 463 nm as their molar extinction coefficients, respectively.
A stock solution of SRM was made in chloroform. Proper aliquots
were dried under a gentle flow of N2, and the dry residue was
dissolved in dimethylsulfoxide (DMSO, Merck) or ethanol, as
indicated. The molar absorptivity of SRM was 20 000 cm-1 at 258
nm, determined from its absorption spectra recorded for a 10 µM
solution in ethanol.
Preparation of Liposomes. Lipids were dissolved in chloroform
and subsequently mixed in this solvent so as to obtain the desired
compositions. The solvent was removed using a gentle stream of
nitrogen where after the dry lipid residues were maintained under
reduced pressure for at least 2 h in order to remove trace amounts
of chloroform. The lipids were hydrated into 20 mM Hepes, 0.1
mM EDTA, pH 7.0. During hydration the dispersing was aided by
a shaking water bath at room temperature so as to yield multila-
mellar vesicles. Large unilamellar vesicles (LUV) were prepared
by extrusion using a LiposoFast (Avestin, Ottawa, Canada) small-
volume homogenizer. The lipid dispersions were passed 19 times
through polycarbonate filters with an average pore diameter of 100
nm (Millipore, Bedford, MA) in order to yield LUVs with an
average diameter of 80 ( 25 nm.12
Fluorescence Spectroscopy. Steady-state fluorescence spectra
were measured in four-window quartz cuvettes with a 1 cm path
length using a fluorescence spectrophotometer (LS-50B, Perkin-
Elmer, MA) equipped with a thermostatted temperature-controlled
cuvette holder. For excitation of SRM, 254 nm was used, corre-
sponding to its absorption maximum, with emission collected from
300 to 500 nm. Emission and excitation band passes were set at 5
nm. Measurements were conducted at 25 °C. For following the
binding kinetics a time drive of 40 min was used. The intensity
values used for the plots were taken at 10 min after drug addition.
As a negative control SRM was added into the buffer without lipids.
Determination of cmc. The critical micelle concentration (cmc)
for SRM was determined at ambient temperature (approximately
22 °C) with an 8-channel surface tension platereader (Delta-8,
Kibron Inc., Espoo, Finland). For these measurements serial
dilutions prepared in 96-well plates (DynePlates, Kibron) in the
indicated concentration range were employed. These data were
analyzed utilizing the Gibbs adsorption isotherm embedded in the
dedicated software from the instrument manufacturer (Delta-8
Manager).
Binding of SRM to Liposomes. Siramesine-liposome interac-
tions were assessed by steady-state fluorescence spectroscopy and
fluorescently labeled lipids. These assays were conducted in quartz
cuvettes and a spectrofluorometer (Cary Eclipse, Varian Inc.,
Victoria, Australia) equipped with a four-position Peltier element
thermostatted cuvette holder. Excitation was set at 344 and 465
nm, corresponding to the absorption maxima of PPDPC and DPPN,
respectively. Emission was collected in the range of 370-500 nm,
allowing detection of the monomer peak of pyrene at 398 nm and
485-600 nm for emission of DPPN with a maximum at 535 nm.
The emission and excitation band passes were both set at either 5
or 10 nm for PPDPC or DPPN, respectively.
The molar partition coefficients for the binding of SRM to
liposomes with different lipid compositions were quantitated as
described previously.13 In brief, quenching of a fluorescent lipid
analog by SRM and subsequent reversal of quenching by unlabeled
liposomes were analyzed using two titrations. First, [lipid] was
maintained constant while increasing [drug]; subsequently, [drug]
was kept constant and [lipid] progressively increased with constant
concentration of the fluorophore. On the basis of the assumption
that at equilibrium the mole fraction of the drug partitioning into a
bilayer of the given lipid composition causes similar relative
quenching irrespective of the total [lipid] or [drug], we can calculate
the partition coefficient for the drug.
Binding of SRM to Lipid Monolayers. Penetration of SRM
into monomolecular lipid films was measured using a Langmuir
tensiometer (DeltaPi, Kibron Inc., Espoo, Finland) with magneti-
cally stirred circular wells with a subphase volume of 1.2 mL
(Multiwell plate, Kibron Inc.). Surface pressure π was monitored
with a metal alloy probe hanging from a high-precision microbal-
ance (KBN129, Kibron Inc.). The indicated lipids were mixed in
chloroform (c ) 1 mM) and spread on the air-water interface using
a microsyringe. The monolayers were allowed to equilibrate for
5-15 min to reach the indicated initial surface pressure values (π0).
A 4.8 µL amount of 0.4 mM SRM (dissolved in DMSO) was then
(11) Kim, J.; Lee, Y. H.; Kwon, T. K.; Chang, J. S.; Chung, K. C.; Min,
D. S. Cancer Res. 2006, 66, 784–793.
(12) MacDonald, R. C.; MacDonald, R. I.; Menco, B. P.; Takeshita, K.;
Subbarao, N. K.; Hu, L. R. Biochim. Biophys. Acta 1991, 1061, 297–
303.
(13) Parry, M. J.; Jutila, A.; Kinnunen, P. K. J.; Alakoskela, J. M. J.
Fluoresc. 2007, 17, 97–103.
Figure 1. Chemical structure of siramesine (SRM).
12954 J. AM. CHEM. SOC. 9 VOL. 130, NO. 39, 2008
A R T I C L E S Parry et al.
injected the subphase (20 mM Hepes, 0.1 mM EDTA, pH 7.0) to
yield a final drug concentration of 1.6 µM. This amount of DMSO
as such had no effect on the surface pressure. The difference
between π0 and the final surface pressure after addition of drug
was taken as the increase in surface pressure (∆π). The data are
represented as ∆π vs π0, thus revealing the effect of increased lateral
packing on penetration of the drug into the monolayer.14
Differential Scanning Calorimetry (DSC). The indicated
amounts of the drug and lipids were mixed in chloroform. These
mixtures were dried under a stream of nitrogen and subsequently
kept under reduced pressure for at least 2 h to remove traces of the
solvent. The samples were hydrated in 20 mM Hepes, 0.1 mM
EDTA, pH 7 at 60 °C for 30 min in a shaking water bath as to
yield multilamellar liposomes utilized in the DSC measurements.
The samples, final lipid concentration 0.4 mM, were equilibrated
on an ice water bath for at least 10 h to ensure equal thermal
histories. The endotherms were recorded using a microcalorimeter
(VP-DSC, Microcal Inc., Northampton, MA) at a heating rate of
30°/h. All scans were repeated to ensure their reproducibility.
Deviation from the baseline was taken as the beginning of the
transition and return to the baseline as its end. The endotherms
were analyzed using the routines of the software provided by the
instrument manufacturer.
Molecular Dynamics (MD) Simulations. MD simulations of
SRM were implemented in lipid bilayers of three different composi-
tions, viz. (i) pure POPC, (ii) POPC with a mole fraction XmaPA )
0.20 of monoanionic PA (maPA), and (iii) POPC with a mole
fraction XdaPA ) 0.20 of dianionic PA (daPA). For the sake of
brevity, these simulations will be referred to as POPC, maPA, and
daPA, respectively. The simulations were carried out with SRM
protonated at the tertiary nitrogen. The distribution of partial charges
near this site is shown in Figure S1, Supporting Information. PA
molecules were uniformly distributed in each 64-lipid bilayer leaflet.
Eight molecules of SRM, corresponding to an SRM:PA ratio of
∼1:3, were added to each hydrated bilayer. Four SRM molecules
were placed 10 Å away from the surface of one bilayer leaflet,
while the other four were placed vicinal to the surface of the other,
adjacent leaflet. All SRM molecules were initially randomly oriented
with respect to the bilayer normal (Figure 2). Sodium and chloride
ions were added as necessary to keep the system electrically neutral.
MD simulations were carried out using the GROMACS 3.3.1
package.15 Details of the simulation parameters and force field
parametrization of maPA, daPA, and SRM are provided in the
Supporting Information.
The simulations were carried out for ∼90 ns for each system,
which was sufficient for SRM molecules to partition into the
bilayers and attain equilibrium conformations. The first 40 ns were
discarded as equilibration time when calculating average properties.
Results
As expected from its chemical structure (Figure 1) SRM is
fluorescent. In ethanol it has absorption bands at 258 and 297
nm, and upon excitation at 258 nm a broad emission band
peaking at 356 nm is seen (Figure 2). The emission intensity
was significantly reduced in water with a weak band centered
at 425 nm (Figure 2).
Further anticipated from its chemical structure SRM is
amphiphilic as demonstrated by its partitioning into the air/water
interface (Figure 3). The recorded isotherm yields 37 ( 6.7 Å2
as the interfacial area of SRM, with cmc observed at 32 ( 1.2
µM. As expected from the above, SRM partitions efficiently
into phosphatidylcholine liposomes with a significant increase
seen in its quantum yield together with a 4 nm blue shift in the
peak wavelength (Figure 2), suggesting SRM becomes accom-
modated in a nonpolar environment, in the hydrocarbon region
of the bilayer.
Kinetics of the binding of SRM to liposomes revealed this
process to be biphasic with an initial fast (approximately 15 s)
and pronounced increase in fluorescence being followed by a
slower, smaller decrease in intensity (data not shown). As
already demonstrated for several other membrane associating
cationic drugs,8,16 anionic phospholipids promote binding of
SRM to bilayers. Accordingly, increasing the content of
phosphatidylserine XPS in liposomes caused a marked increase
in the membrane binding of SRM as reflected by a pro-
nounced increase in its fluorescence (Figure 4). The presence
of 150 mM NaCl diminished the binding of SRM to LUVs
with progressively less effect upon increasing XPS, thus also
(14) Brockman, H. Curr. Opin. Struct. Biol. 1999, 9, 438–443.
(15) Lindahl, E.; Hess, B.; van der Spoel, D. J. Mol. Model. 2001, 7, 306–
317.
(16) Jutila, A.; Ryto¨maa, M.; Kinnunen, P. K. J. Mol. Pharmacol. 1998,
54, 722–732.
Figure 2. Absorption spectrum of 10 µM SRM in ethanol (left), and
emission spectra (normalized at RFI ) 100) in hexane, ethanol, buffer (20
mM Hepes, 0.1 mM EDTA pH 7.0), and with 20 µM POPC vesicles, as
indicated. All spectra were recorded with the drug added in a small volume
(2 µL, total volume 2 mL) of chloroform yielding final [SRM] ) 10 µM in
ethanol and [SRM] ) 6 µM in buffer and with liposomes. T ) 25 °C.
Figure 3. Adsorption isotherm of SRM on 20 mM Hepes, 0.1 mM EDTA,
pH 7.0 buffer measured at room temperature (approximately 22 °C). The
error bars represent standard deviations for two consecutive measurements.
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revealing electrostatics to contribute to the association of
SRM to membranes containing this negatively charged
phospholipid.
In order to study the localization of SRM in liposomes we
used SRM as a quencher for trace amounts of different
fluorescent lipid analogs. We first employed PPDPC, a phos-
pholipid analog containing a pyrene-decanoyl chain in the
sn-2 position. As there is no spectral overlap between SRM
and pyrene the observed quenching (Figure 5) is collisional,
reflecting efficient binding of SRM to POPC vesicles and
causing at a drug:phospholipid ratio of 1:2 a maximally 60%
decrement in PPDPC emission. While the hydrophobicity of
the pyrene moiety of PPDPC causes this fluorophore to reside
in the hydrocarbon region of the membrane, its polarizability
together with cation-π interactions should prefer a more
interfacial orientation.17,18 Interestingly, including PS (X )
0.50) to the vesicles attenuated the quenching of PPDPC by
SRM (Figure 5) and increasing the content of PS further to
X ) 0.99 augmented this effect with only a minor decrement
caused by SRM in PPDPC fluorescence. For vesicles with
XPS ) 0.2 the quenching was biphasic with the initial small
decrement in fluorescence caused by 4 µM SRM (corre-
sponding to an apparent drug:PS molar ratio of 1:1) being
followed by a progressive and pronounced quenching upon
further increase in [drug]. This was further elucidated for
vesicles with XPA ) 0.02, 0.05, 0.10, and 0.20. Similarly to
XPS ) 0.2 quenching was biphasic (Figure 5B) with the
discontinuity observed at SRM concentrations varying lin-
early with XPA and corresponding to an apparent 1:1 drug:
PA molar ratio. The above data suggest formation of
stoichiometric complexes by SRM and PA on the membrane
surface, preventing penetration of SRM into the membrane
hydrocarbon region where the pyrene moiety of PPDPC is
accommodated.
Subsequently, we used another lipid analog DPPN bearing a
fluorescent NBD label in the headgroup. For this probe (X )
0.01) and POPC vesicles, the decrement in fluorescence caused
by 4 µM SRM was 50% (Figure 6), and efficient quenching
was observed also for PS containing LUVs (XPS ) 0.20) with
little difference when compared to neat POPC LUVs.
To compare the affinities of SRM to different phospholipids
we determined the partition coefficients for SRM between the
aqueous solution and vesicles containing POPC, POPS, POPG,
egg-PA, Brain-PI, POPE, DOPMe, DOPet, lyso-PA, and lyso-
PG using the headgroup labeled DPPN (X ) 0.01) as a
fluorophore (Table 1). In keeping with the above fluorescence
studies SRM preferentially binds to acidic lipids with the highest
affinity KP ) 240 ( 80 × 106 measured for PA.
To further assess the specificity of the binding and preference
of different cationic amphiphilic drugs for anionic phospholipids
we determined the partitioning of chlorpromazine, doxorubicin,
clozapine, and haloperidol to vesicles containing PG, PA, or
PS. The highest affinities of the above drugs were measured
for PS followed by PG, while the lowest affinity was observed
for PA-containing vesicles (Table 2).
The above quenching experiments suggest that SRM
intercalates into the hydrocarbon region of neat POPC
bilayers, while in the presence of anionic lipids two modes
of binding are evident: a high-affinity binding site in the
membrane surface with SRM bound to the acidic phospho-
lipid headgroup and a second site with the drug intercalating
into the hydrocarbon region. To verify the above conclusions
from the fluorescence quenching experiments study we
measured the penetration of SRM into lipid monolayers
residing on the air/buffer interface (Figure 7). In accordance
with the above fluorescence data a pronounced increase in
surface pressure due to SRM added into the subphase was
observed for pure PC films, while XPS ) 0.2 dramatically
decreased the penetration. This readily complies with an
interfacial location of SRM in films containing the acidic
phospholipid. Intriguingly, the association of SRM to mono-
layers containing PA is different from those with PS (Figure
7) with high values for ∆π being measured. This is most
likely caused by the more extensive partitioning of SRM to
PA together with a pronounced relative increase in the
effective headgroup size of this lipid upon binding of SRM.
The impact of SRM on the thermal phase behavior of
liposomes studied by DSC is in keeping with the above data
(see Supporting Information Figure S3). The main phase
transition temperature Tm decreases as a function of XSRM with
broadening of the peak to lower temperatures for DPPC MLVs.
The pretransition temperature Tp decreases, and at XSRM ) 0.05
the pretransition disappears, in keeping with the perturbation
caused by the drug in the hydrocarbon region of the bilayer
(Supporting Information Figure S4).
The main conclusions from the above experiments could
be substantiated in MD simulations. Accordingly, SRM
molecules partitioned into the bilayer phase within 30 ns in
all simulations. The equilibrium distribution of the drug along
the bilayer normal is shown in Figure 8. The depth of
penetration was largest for POPC and lowest for daPA with
the average distance between SRM and the bilayer center
along the bilayer normal being 11.88 ( 1.32, 14.83 ( 1.40,
and 15.22 ( 2.25 Å for POPC, maPA, and daPA, respec-
tively. Thus, SRM intercalated deeper into the hydrocarbon
core of POPC, even at a low SRM:PA molar ratio of 1:3, in
agreement with the fluorescence quenching data.
(17) Hoff, B.; Strandberg, E.; Ulrich, A.; Tieleman, D.; Posten, C. Biophys.
J. 2005, 88, 1818–1827.
(18) Yau, W.; Wimley, W.; Gawrisch, K.; White, S. Biochemistry 1998,
37, 14713–14718.
Figure 4. Change in the fluorescence intensity of SRM added to liposomes
with increasing contents of the anionic POPS (b), in buffer and in the
presence of 150 mM NaCl (O). [SRM] ) 2.5 µM corresponding to drug:
phospholipid stoichiometry of 1:8. The values for fluorescence intensity
were taken 10 min after drug addition. Excitation at 254 nm and emission
at 350 nm. T ) 25 °C. Spectra were recorded in 20 mM Hepes, 0.1 mM
EDTA, pH 7.0, total [lipid] ) 20 µM.
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The strongest interactions of PA with SRM were with the
protonated nitrogen of SRM. Figure 9 shows the radial distribu-
tion functions (RDF) of the protonated nitrogen (Np) of SRM
with the two possible hydrogen-bonding sites on PA, i.e., the
phosphate (PO4-) moiety and the ester group. The higher
negative charge density of (PO4-) resulted in a strong
N-HsO-P hydrogen bonding between the SRM Np and the
(PO4-) oxygen atoms. This H bonding was present in both
maPA and daPA but stronger in the latter. In daPA, the higher
charge (-2) also caused formation of an SRM aggregate near
Figure 5. Quenching by SRM of the pyrene-labeled phospholipid analog PPDPC (X ) 0.01) in POPC vesicles: (A) with XPOPS ) 0 (O), 0.20 (b), 0.50(2),
and 0.99 (1) and (B) XPA ) 0 (O), 0.02 (b), 0.05 (2), 0.10 (1), and 0.20 (9). Total phospholipid was 20 µM in 20 mM HEPES, 0.1 mM EDTA, pH 7.0,
T ) 25 °C.
Figure 6. Quenching of DPPN (X ) 0.01) fluorescence by SRM in POPC
LUVs (O), LUVs containing XPS ) 0.2 (b), XPS ) 0.99 (1), and XPA )
0.2 (9). The error bars represent the standard deviation of at least two
consecutive measurements. Conditions as described in the legend for Fig-
ure 5.
Table 1. Molar Partition Coefficients for the Binding of Siramesine
to Liposomes
lipid composition Kp/106
XLIPID ) 1.0
POPC 1.2 ( 0.09
POPS 2.1362 ( 0.0004
POPG 120 ( 64
XPC ) 0.8
POPC/POPE 1.15 ( 0.04
POPC/POPS 3.3 ( 0.4
POPC/Lyso-PG 5.0 ( 0.4
POPC/Lyso-PA 7.2 ( 0.2
POPC/DOPEt 8.2 ( 0.7
POPC/POPG 9.4 ( 2.1
POPC/DOPMe 9.9 ( 1.1
POPC/POPI 29 ( 3
POPC/egg-PA 240 ( 80
Table 2. Molar Partition Coefficients (Kp/106) for Binding of the
Indicated Cationic Amphiphilic Drugs to Liposomes Containing
Different Anionic Phospholipids; Siramesine Is Included for
Comparison
liposomes (PS, PG, or PA, X ) 0.2)
drug POPC/egg-PA POPC/POPS POPC/POPG
doxorubicin 1.21 ( 0.01 2.96 ( 0.35 1.92 ( 0.07
chlorpromazine 5.96 ( 0.65 23.7 ( 5.79 13.89 ( 3.77
clozapine 2.77 ( 0.21 11.16 ( 4.01 3.33 ( 0
haloperidol 5.5 ( 3.76 2.02 ( 1.47 11.97 ( 4.04
siramesine 240 ( 80 3.3 ( 0.4 9.4 ( 2.1
Figure 7. Intercalation of SRM into phospholipid monolayers. SRM (1.6
µM) added into the subphase and the increase in surface pressure ∆π vs
initial surface pressure π0 was recorded. The films were composed of POPC
(O), POPC with POPS (X ) 0.2 (b)), and POPC with egg-PA (X ) 0.20
(9)). The lines represent linear fits to the data.
J. AM. CHEM. SOC. 9 VOL. 130, NO. 39, 2008 12957
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the interface, which could prevent SRM from penetrating deeper
into the bilayer.
Discussion
Effects of drugs are conventionally rationalized in terms of
small molecule ligand-receptor protein interactions. However,
there are recent data suggesting that several drugs partition
efficiently into membrane lipids and affect both membrane
organization and dynamics, thus influencing indirectly the
environment and conformation of ion channels and receptors
as well as other membrane-embedded proteins.9,19-21 Several
drugs associating with acidic phospholipids have been further
demonstrated to displace in a competitive manner peripheral
proteins from membranes.16 Drug-phospholipid complex for-
mation may also underlie toxic side effects, as exemplified by
phospholipidosis, the intracellular accumulation of phospholipids
resulting in inhibition of phospholipases and changes in phos-
pholipid synthesis.22,23
Notably, clinically relevant effects of drugs are commonly
observed at far lower drug concentrations than changes in
membrane properties. Accordingly, the high and apparently quite
specific affinity of SRM to PA is unprecedented. More specif-
ically, our data demonstrate that while SRM partitions into the
hydrocarbon region of zwitterionic PC membranes, in the
presence of negatively charged phospholipids, PA in particular,
it is very efficiently retained in the interface (Figure 8),
apparently forming a complex with acidic phospholipids. The
affinity of SRM to phosphatidic acid was found to be high, its
partitioning into membranes with XPA ) 0.20 being of an order
of magnitude higher as compared to membranes with an equal
content of other acidic phospholipids (Table 1; Figure 10). The
measured partition coefficient Kp ) 240 ( 80 × 106 corresponds
to a dissociation constant of approximately 0.23 µM, which is
comparable to the affinities reported for small molecule
ligand-macromolecule interactions as measured for doxorubicin
and DNA (Kd ) 68 µM24) and for the binding of clozapine to
the dopaminergic D2 receptor (Kd ) 44 nM25). The high-affinity
binding to PA seems to be specific with little correlation to
factors such as headgroup size or dipole potential (as measured
by di-8-ANEPPS, data not shown).
With the above data providing evidence for SRM-PA
complex formation, we performed MD simulations to reveal
potential modes of interaction. It has been suggested that upon
hydrogen-bond formation with a charged amine PA would
be deprotonated into a divalent anion, yielding daPA.26,27
This could be involved also in the SRM-PA complex
formation, favoring electrostatic interactions with the positive
charge of SRM. In keeping with the above, MD simulations
suggest that the binding of SRM to PA is driven by strong,
electrostatically driven H-bond formation between Np and
the negatively charged unshielded (PO4-) moiety of PA. The
strength of this H bonding was sufficient to retain SRM near
the interface in simulations on bilayers containing PA.
Intriguingly, aggregation of SRM was observed when daPA
is included in the bilayer. The interactions between Np of
SRM and the lipid headgroup phosphate were evident also
for neat POPC but weaker than for daPA (data not shown),
thus allowing deeper penetration of SRM into the bilayer. A
more detailed MD study involving simulations at progres-
sively increasing SRM:lipid ratios is needed to comply with
the quenching and monolayer data, in particular to address
the exact stoichiometry of the complex.
PA has been assigned a central role as a secondary
messenger in the regulation of various cellular functions. A
number of proteins promoting cell survival, such as Hsp,28
mTOR,29 Raf,30 Ras,31 and Sos,32 require PA for their
activity. Yet, it is crucial also in the activation of RAS- and
TNF-R-mediated apoptosis.33 PA may further be involved
in the pathogenesis of systemic vasculitis.34 The major
pathway producing PA in vitro involves phospholipase D,
which cleaves the headgroup of either PE or PC to yield PA.
Other pathways producing PA in cells involve acylating lyso-
PA by lyso-PA acyl transferase35 and phosphorylation of
diglyceride by diglyceride kinase.36 Different cancer cell lines
utilize distinct pathways to generate PA, allowing them to
escape apoptosis,37 and also exogenous PA has been shown
to act as an antiapoptotic signal. Consequently, there is an
intense search for PLD inhibitors that could be used as
anticancer drugs to decrease the levels of cellular PA.
The role of PA in cell survival may also provide a mechanism
to explain the anticancer activity of SRM. The dissociation
constant for SRM to the σ receptor is 1.1 nM2, while the
concentrations required for anticancer effect are in the range
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Figure 8. Equilibrium distribution of SRM into the three different bilayers
with data from maPA (red line) and daPA (green line) simulations
superimposed on the SRM distribution in the POPC simulation (black line).
The bilayer center is at z ) 0.
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of 1-2 µM for cultured cells. For mice, assuming complete
absorption, the applied dose roughly corresponds to a
concentration of 14 µM,38 suggesting that a great excess over
the saturation of all the σ-binding sites was required. The
concentrations needed for anticancer activity would thus
suffice to have a significant occupancy of PA. Accordingly,
sequestering of PA by SRM could impede proper functioning
of proteins requiring this phospholipid for activity and thus
provide a simple molecular mechanism underlying the
augmented apoptosis observed in cancer cells due to this
drug.7,38 While further structural analysis is needed to
elucidate the exact nature of SRM-PA interaction, our data
demonstrate that it is possible to generate small molecule
drugs with affinity to a specific phospholipid species. Our
findings potentially thus constitute a new paradigm of small
Figure 9. (A) Radial distribution functions between the protonated nitrogen of SRM and the headgroup atoms of maPA in the corresponding simulation.
The phosphorus atom and ester carbon atoms were used for assigning the distribution with respect to the lipid phosphate (red line) and ester (black line)
groups. (B) Simulation snapshot showing the H-bonding interaction between the SRM protonated nitrogen and the daPA phosphate group. The phosphorus
and oxygen atoms of PO4- are shown in gold and red, respectively, while SRM and the phosphate group are represented in licorice, and the rest of the lipid
is shown in yellow. The hydrogen bonds are illustrated as green springs.
Figure 10. Schematic illustration of the relative position of membrane-bound SRM with respect to different fluorophores complying with the positional
restrictions to collisional quenching in a bilayer leaflet. From left to right are depicted PPDPC, SRM, DPPN, and SRM-PA complex. On the left SRM is
illustrated in an extended conformation, intercalated into the hydrocarbon region, quenching both the pyrene moiety of PPDPC and the NBD moiety of
DPPN, respectively. In contrast, when bound to PA SRM is retained in the interface, quenching of only DPPN being possible.
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molecular anticancer drugs based on specific sequestering
of lipid second messengers.
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